PR(AG)119/2019 “Screening for liver fibrosis Population-based study across European Countries” (LiverScreen)

Synopsis:

Change of data controller. Joint responsibility of participating centres.

This is a research study evaluating the utility and feasibility of a screening method to detect liver fibrosis by measuring liver stiffness in the European population. The main objective of the study is to assess the prevalence of liver fibrosis in the general population using FibroScan®, a simple, non-invasive and widely used method that measures liver stiffness and identifies hepatic fibrosis. Part of the data will be sent in a coded form to Echosens, the French manufacturer of FibroScan®. Echosens will use these data internally to improve the FibroScan® technique for detecting liver fibrosis in the general population. This data transfer will ensure patient confidentiality at the level of protection required by current Spanish legislation.

This is a non-commercial research study designed and conducted by the LiverScreen Consortium, a European consortium comprising seven countries: Spain, France, Germany, Italy, the Netherlands, Denmark and the United Kingdom.

Participating institutions:

  • Clínic Foundation for Biomedical Research (FCRB), Spain
  • Assistance Publique – Hôpitaux de Paris (AP-HP), France
  • Universität des Saarlandes (USAAR), Germany
  • Azienda Ospedale – Università Padova (AOUP), Italy
  • Catalan Health Institute (ICS), Spain
    • Vall d’Hebron University Hospital Foundation – Research Institute (VHIR), Spain
    • Germans Trias i Pujol Health Sciences Research Institute Foundation (IGTP), Spain
    • Jordi Gol i Gurina Primary Health Care Research Institute Foundation (IDIAPJGol), Spain
  • Odense Universitetshospital (OUH) Denmark
  • The University of Nottingham (NIHR), United Kingdom
  • Erasmus Universitair Medisch Centrum Rotterdam (EMC) Netherlands
  • Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz (UMCU) Germany
  • Pompeu Fabra University (UPF), Spain
  • European Liver Patients Association (ELPA), Belgium
  • European Association for the Study of the Liver (EASL), Switzerland
  • Echosens (Echo), France
  • Parc de Salut Mar Consortium (IMIM), Spain
  • University College London (UCL), United Kingdom
  • University of Zagreb School of Medicine (UZSM), Croatia
  • Barcelona Supercomputing Center SL (BSC), Spain
  • Genesis BioMed (Gen), Spain
  • Innovation Acta S.r.l. (INN-ACTA), Italy

Data origin:

Consent of the participating subject.

Subscribe to our newsletters and be a part of Vall d'Hebron Campus

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”.
Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health).
Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information.
Legal basis: Consent of the data subject.
Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen.
Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time.
Source: The data subject.
Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.